Compare Biocon with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs IPCA LABS - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON IPCA LABS BIOCON /
IPCA LABS
 
P/E (TTM) x 31.4 23.7 132.2% View Chart
P/BV x 3.7 8.5 44.0% View Chart
Dividend Yield % 0.3 0.1 184.3%  

Financials

 BIOCON    IPCA LABS
EQUITY SHARE DATA
    BIOCON
Mar-19
IPCA LABS
Mar-19
BIOCON /
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs7071,042 67.9%   
Low Rs554590 93.8%   
Sales per share (Unadj.) Rs91.9298.6 30.8%  
Earnings per share (Unadj.) Rs16.735.0 47.7%  
Cash flow per share (Unadj.) Rs24.249.4 48.9%  
Dividends per share (Unadj.) Rs1.003.00 33.3%  
Dividend yield (eoy) %0.20.4 43.1%  
Book value per share (Unadj.) Rs101.6247.1 41.1%  
Shares outstanding (eoy) m600.00126.35 474.9%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x6.92.7 251.1%   
Avg P/E ratio x37.723.3 161.8%  
P/CF ratio (eoy) x26.116.5 158.0%  
Price / Book Value ratio x6.23.3 187.9%  
Dividend payout %6.08.6 69.8%   
Avg Mkt Cap Rs m378,330103,108 366.9%   
No. of employees `0006.113.4 45.6%   
Total wages/salary Rs m11,6537,874 148.0%   
Avg. sales/employee Rs Th8,994.32,807.0 320.4%   
Avg. wages/employee Rs Th1,900.7585.8 324.5%   
Avg. net profit/employee Rs Th1,635.3329.0 497.1%   
INCOME DATA
Net Sales Rs m55,14437,732 146.1%  
Other income Rs m1,444577 250.3%   
Total revenues Rs m56,58838,309 147.7%   
Gross profit Rs m15,8836,901 230.2%  
Depreciation Rs m4,4781,824 245.5%   
Interest Rs m709189 375.7%   
Profit before tax Rs m12,1405,465 222.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1231,042 203.7%   
Profit after tax Rs m10,0264,422 226.7%  
Gross profit margin %28.818.3 157.5%  
Effective tax rate %17.519.1 91.7%   
Net profit margin %18.211.7 155.1%  
BALANCE SHEET DATA
Current assets Rs m48,22823,778 202.8%   
Current liabilities Rs m30,37610,975 276.8%   
Net working cap to sales %32.433.9 95.4%  
Current ratio x1.62.2 73.3%  
Inventory Days Days68104 65.8%  
Debtors Days Days8666 129.7%  
Net fixed assets Rs m64,13020,368 314.9%   
Share capital Rs m3,000253 1,187.2%   
"Free" reserves Rs m57,98030,971 187.2%   
Net worth Rs m60,98031,224 195.3%   
Long term debt Rs m15,7661,409 1,119.3%   
Total assets Rs m121,92445,507 267.9%  
Interest coverage x18.130.0 60.5%   
Debt to equity ratio x0.30 573.1%  
Sales to assets ratio x0.50.8 54.5%   
Return on assets %8.810.1 86.9%  
Return on equity %16.414.2 116.1%  
Return on capital %16.817.3 96.7%  
Exports to sales %28.145.9 61.3%   
Imports to sales %18.916.6 113.5%   
Exports (fob) Rs m15,50617,308 89.6%   
Imports (cif) Rs m10,3996,266 165.9%   
Fx inflow Rs m15,50617,308 89.6%   
Fx outflow Rs m10,3996,266 165.9%   
Net fx Rs m5,10711,042 46.3%   
CASH FLOW
From Operations Rs m11,5464,923 234.5%  
From Investments Rs m-7,138-1,563 456.7%  
From Financial Activity Rs m-2,417-1,832 131.9%  
Net Cashflow Rs m2,1031,528 137.7%  

Share Holding

Indian Promoters % 40.4 45.9 88.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.4 73.7%  
FIIs % 10.7 25.3 42.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.4 114.4%  
Shareholders   109,995 36,892 298.2%  
Pledged promoter(s) holding % 0.0 2.1 1.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SUVEN LIFE SCIENCES  NEULAND LABS  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher, Dow Futures Up by 53 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 191 points, up 0.4% at 48,868 levels.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 6, 2021 03:32 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS